ABO-2203

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameABO-2203
Drug Alias NameABO2203ABO-2203
ClassificationCell and gene therapy > Gene therapy > mRNABiologics > T cell engagers
Mechanisms of ActionAnti-CD19Anti-CD3
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbogen Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Rui Jin Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A